COMMUNIQUÉS West-GlobeNewswire

Zymeworks Completes Acquisition of Theravance Biopharma
23/09/2026
Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a [...]
New model-based analysis further supports the potential of TECVAYLI®▼ (teclistamab) plus daratumumab to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
23/09/2026
Analysis showed ~87% of patients treated with TECVAYLI ® ▼ plus daratumumab as early as second line were estimated to have comparable mortality risk to the general population 1 A separate analysis shows the survival [...]
Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
23/09/2026
The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the [...]
TwitchView® Quantitative Neuromuscular Monitoring Now Standardized Across Two Additional Midwest Academic Health Systems
23/09/2026
SEATTLE, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Blink Anesthesia announced today that two additional academic integrated delivery networks (IDNs) in the Midwest have standardized the TwitchView® Train of Four (TOF) Monitor [...]
MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
23/09/2026
The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the [...]
Clareo Plastic Surgery Recognized as Best Plastic Surgeon in Boston
23/09/2026
Pouted Magazine Ranks Clareo No. 1 Among Five Boston-Area Plastic Surgery Practices Chestnut Hill, MA, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Clareo Plastic Surgery has earned the top spot in Pouted Magazine's 2026 [...]
CROSSJECT et la BARDA consolident le plan de développement pédiatrique de ZEPIZURE® selon les attentes de la FDA avec un financement renforcé jusqu’en 2030
23/09/2026
CROSSJECT et la BARDA ont consolidé le plan de développement clinique de ZEPIZURE® pour l’indication pédiatrique, conformément aux recommandations de la FDA Un financement supplémentaire non dilutif de 4,7 millions de [...]
CROSSJECT and BARDA align ZEPIZURE®’s Pediatric development plan with FDA including funding through 2030
23/09/2026
CROSSJECT and BARDA have consolidated the clinical development plan for the pediatric indication of ZEPIZURE®, in alignment with the FDA guidance $4.7 million in additional, non-dilutive funding, to cover the planned [...]
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
23/09/2026
All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated Strong immunogenicity demonstrated, with 100% response rate after three immunizations Clear antibody penetration [...]
Grey Matters Announces the Closing of its Equity and Convertible Debenture Private Placement totalling CAD $1.12 Million
23/09/2026
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: [...]
Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026
23/09/2026
John Chambers, PhD, and Nilanjana Sadhu, PhD, to share early insights from pioneering population-scale proteomic study of 10,000 participants in Singapore REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Seer, [...]
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
23/09/2026
Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and [...]
Psyence BioMed Announces Strategic Ibogaine Investment
23/09/2026
Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential ibogaine clinical [...]
Verano to Report Third Quarter 2026 Financial Results on October 29, 2026
23/09/2026
CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial [...]
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
23/09/2026
SAN CARLOS, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has terminated its proposed [...]
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
23/09/2026
Oral presentation to highlight updated clinical data from 11 patients with Sjögren disease (SjD) treated with AlloNK and rituximab, with six months or more of follow-up SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- [...]
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
23/09/2026
WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave’s INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 [...]
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
23/09/2026
As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks Application expands Artelo’s [...]
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
23/09/2026
- In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinically significant 34 [...]

Pages